CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MBQ-167
CAS:<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Fórmula:C22H18N4Pureza:98.07% - 99.52%Cor e Forma:SolidPeso molecular:338.41Simurosertib
CAS:<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Fórmula:C17H19N5OSPureza:99.93% - 99.93%Cor e Forma:SolidPeso molecular:341.43Amantadine hydrochloride
CAS:<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Fórmula:C10H18ClNPureza:99.98%Cor e Forma:Solid CrystallinePeso molecular:187.71CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Fórmula:C24H22FN7O2Cor e Forma:SolidPeso molecular:459.48(E/Z)-THZ1 2HCl
CAS:<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Fórmula:C31H30Cl3N7O2Pureza:99.51%Cor e Forma:SolidPeso molecular:638.98JH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Fórmula:C22H22ClN7OCor e Forma:SolidPeso molecular:435.92CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Fórmula:C32H34FN7O4Cor e Forma:SolidPeso molecular:599.655LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Fórmula:C43H56N10O5Cor e Forma:SolidPeso molecular:792.97CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Fórmula:C13H15N3OSPureza:99.92%Cor e Forma:SolidPeso molecular:261.34dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Cor e Forma:SolidPeso molecular:318.78CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Fórmula:C19H27N7OCor e Forma:SolidPeso molecular:369.464BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Cor e Forma:LiquidJH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.161[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Fórmula:C98H138F3N21O39Pureza:98%Cor e Forma:SolidPeso molecular:2291.25IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.625CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99CDK9 ligand 3
CAS:<p>CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.</p>Fórmula:C18H18BrCl2N5O3Cor e Forma:SolidPeso molecular:503.177
